Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Newcastle disease virus AMHA1
- Development stage
- Preclinical
- Lead developer
- Iraqi Center for Cancer and Medical Genetics Research
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intramuscular, Intranasal, Ophthalmic, Oral, Inhalation
01
Overview
Newcastle disease virus AMHA1 is an attenuated Iraqi strain of the Newcastle disease virus (NDV) being developed as an oncolytic virotherapy. NDV is an avian paramyxovirus that exhibits natural tumor selectivity, replicating preferentially in cancer cells with impaired interferon signaling while sparing healthy cells. The AMHA1 strain has shown potent cytotoxic activity in vitro against human digestive system tumors, including esophageal and colorectal carcinomas, by inducing apoptosis and direct viral lysis. It is currently under investigation by researchers at the Iraqi Center for Cancer and Medical Genetics Research for its potential as a first-line or adjunctive cancer treatment.
- Other names
- NDV AMHA1Iraqi NDV-attenuated strain AMHA1
02
Targets
NDV HN site II (Newcastle disease virus hemagglutinin-neuraminidase protein site II)α2,6-Sia (Alpha-2,6-linked sialic acid)
Beyond the preview
Go deeper on Newcastle disease virus AMHA1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Newcastle disease virus AMHA1.